Dr. John Reed, CEO of the Sanford-Burnham Medical Research Institute, San Diego, is resigning his post to become head of Roche Pharma Research and Early Development. Reed begins his new job April 2, and he will be based in Basel, Switzerland.
Reed, 54, replaces interim head Mike Burgess, who has decided to leave Roche, according to a Roche news release
. Reed will also be part of the Roche corporate executive committee, and will keep his association with the institute through an adjunct professor post.
According to the Beaker blog on the Sanford-Burnham website
, Dr. Kristiina Vuori, president of the institute, will assume all leadership responsibilities on an interim basis.
“I am grateful to have led Sanford-Burnham over the past decade, especially in the growth of the institute's work in translational research,” Reed said in the blog post. “While I am sad to be leaving the institute, I look forward to the potential for collaborations in the future between the two organizations. I am confident in the financial strength of the institute following the strongest year of grant revenue in its history, as well as in Dr. Vuori's ability to lead through the time ahead.”
Reed became CEO in 2002 (PDF)
and, during his tenure, the institute has been one of the largest recipients of National Institutes of Health grants and opened a second research campus
in the Medical City at Lake Nona complex in Orlando, Fla.
Vuori, who joined Sanford-Burnham in 1996, has been the director of its National Cancer Institute-designated cancer center since 2006 and was appointed institute president in April 2010, according to her biography on the institute website